Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial
Tweet Send to a Friend
Agenus Inc. (Nasdaq: AGEN) reported total revenue of $34.5 million for the second quarter ended June 30, 2026, up from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
